Document Detail

Treating mood disorders during pregnancy: safety considerations.
MedLine Citation:
PMID:  16048355     Owner:  NLM     Status:  MEDLINE    
Mood disorders in pregnancy may have a negative effect on self care and pregnancy outcome that affects the mother directly and the child indirectly. Thus, some women may require pharmacological treatment. Pharmacotherapy of mood disorders during pregnancy implies specific considerations. This paper presents an updated review of available studies on the treatment of mood disorders and present knowledge on teratogenicity, neonatal effects and long-term neurobehavioural effects for the different psychotropic drugs, including treatment with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), other antidepressants, benzodiazepines, lithium, carbamazepine/valproic acid, lamotrigine and novel antipsychotics. However, the existing knowledge on the use of antidepressants and mood stabilising agents during pregnancy is hampered by a lack of results from randomised controlled trials.SSRIs and TCAs have not been associated with an increased risk of major malformations, but poor neonatal adaptation has been described. Benzodiazepines used in the first trimester have been associated with orofacial clefts. Mood stabilisers such as lithium, carbamazepine and valproic acid (sodium valproate) are associated with an increased risk of fetal malformations. Both benzodiazepines and lithium may cause adaptation problems in the newborn. In utero exposure to novel antipsychotics has not been associated with congenital malformations; however, the data are still limited. The knowledge about long-term neurobehavioural effects in the offspring is still limited for all agents and requires further investigation. Possible adverse effects of fetal exposure must be balanced against the adverse effects of an untreated maternal mood disorder.
Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Related Documents :
19507305 - Management issues for women with epilepsy--focus on pregnancy (an evidence-based review...
22270445 - Complex ovarian pregnancy.
8162395 - Pregnancy, epilepsy, management and outcome: a 10-year perspective.
7372375 - Medication during pregnancy and breast-feeding--a new swedish system for classifying dr...
7962425 - Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (bus...
16726165 - Prevalence of postservice pyometra in a herd of beef cows infected with trichomoniasis:...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Drug safety     Volume:  28     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2005  
Date Detail:
Created Date:  2005-07-28     Completed Date:  2005-10-31     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  695-706     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Anxiety Agents / adverse effects,  pharmacokinetics,  therapeutic use
Anticonvulsants / adverse effects,  pharmacokinetics,  therapeutic use
Antidepressive Agents / adverse effects,  pharmacokinetics,  therapeutic use
Antipsychotic Agents / adverse effects,  pharmacokinetics,  therapeutic use
Depressive Disorder / diagnosis,  drug therapy,  psychology
Mood Disorders / drug therapy*,  psychology*
Pregnancy Complications / drug therapy*,  psychology*
Psychotropic Drugs / adverse effects*,  pharmacokinetics,  therapeutic use*
Reg. No./Substance:
0/Anti-Anxiety Agents; 0/Anticonvulsants; 0/Antidepressive Agents; 0/Antipsychotic Agents; 0/Psychotropic Drugs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.
Next Document:  Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review.